Biomolecules & Therapeutics

The Korean Society of Applied Pharmacology (한국응용약물학회)
권호 표지
DOI QR코드

DOI QR Code

The Change of Bone Mineral Density by Bisphosphonates Therapy with Calcium-Antagonists in Osteoporosis

  • Kim, Soon-Joo (College of Pharmacy and Research Institute of Pharmaceutical Science, Sookmyung Women's University) ;
  • La, Hyen-Oh (Pharmacology, College of Medicine, The Catholic University) ;
  • Kang, Young-Sook (College of Pharmacy and Research Institute of Pharmaceutical Science, Sookmyung Women's University)
  • Published : 2008.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

Imbalance in calcium and phosphorous metabolism due to aging or menopause leads to osteoporosis. In contrast to patients with normal blood pressure, hypertensive patients have a higher loss of calcium in the urine with its attendant risk of osteoporosis. The high blood pressure is associated with the risk of bone loss and abnormalities in calcium metabolism leading to calcium loss. So we retrospectively investigated the changes of bone mineral density (BMD) which drugs can have clinical influences over osteoporosis treatments of patients with calcium-antagonists as common antihypertensive drugs and with bisphosphonates which causes a most effective inhibition of osteoclasts resorption. As a result over 70 years of age group and within bisphosphonates group, alendronate 70 mg once-weekly group showed significant increase of BMD in lumbar area. Combination group of cilnidipine and $maxmarvil^{(R)}$ showed very significant decrease of BMD. In conclusion, it is desirable that combination therapy with calcium-antagonists is used carefully in the treatment of osteoporosis with high blood pressure.

Keywords

References

  1. Albers, M.M., Johnson, W.V., and Jackson, R.D. (1991). Chronic use of the calcium channel blocker nifedipine has no significant effect on bone metabolism in men. Bone. 12, 39-42 https://doi.org/10.1016/8756-3282(91)90053-L
  2. Barry, E.L.R. (2000). Expression of mRNAs for the $\alpha$1 subunit of voltage-gated calcium channels in human osteoblast-like cell lines and in normal human osteobasts. Calcif Tissue Int. 66, 145-150 https://doi.org/10.1007/s002230010029
  3. Bone, H.G., Robert, W.D., Joseph, R.T., Steven, T.H., Robert, S.W., Angelo, A.L., Michael, R.M., Donald, B.K., Barry, J.G., Erika, H., and William J.P. (1997). Dose-response relationships for alendronate treatment in osteoporotic elderly women. J Clini Endocrinol Metab. 82(1), 265-274 https://doi.org/10.1210/jc.82.1.265
  4. Bone, H.G., Hosking, D., Devogelaer, J.P., Tucci, J.R., Emkey, R.D., Tonino, R.P., Rodrigue-Portales, J.A., Downs, R.W., Gupta, J., Santora, A.C., and Liberman U.A. (2004). Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl Med., 350, 1189-1899 https://doi.org/10.1056/NEJMoa030897
  5. Cappuccio, F.P., Meilahn, E., Zmuda, J.M., and Cauley, J.A. (1999). High blood pressure and bone-mineral loss in elderly white women: a prospective study. Study of osteoporotic fractures research group. Lancet. 354, 971-975 https://doi.org/10.1016/S0140-6736(99)01437-3
  6. Caren, G.S. (2002). Bisphosphonates and Osteoporosis., N Eng J Med. 346(9) 642 https://doi.org/10.1056/NEJM200202283460902
  7. Duriez, J., Flautre, B., Blary, C., and Hardouin, P. (1993). Effects of the calcium channel blocker nifedipine on epiphyseal growth plate and bone turnover: a study in rabbit. Calcif Tissue Int. 52, 120-124 https://doi.org/10.1007/BF00308320
  8. Eva, S., Diane, M.C., Mohammed, P.A., and Donald, B.K. (2001). No effect of verapamil on the local bone response to in vivo mechanical loading. J Orth R. 19, 328-336 https://doi.org/10.1016/S0736-0266(00)90005-6
  9. Gotoh, M., Mizuno, K., Ono, Y., and Takahashi, M. (2005). High blood pressure, bone-mineral loss and insulin resistance in women. Hypertens Res. 28(7), 565-570 https://doi.org/10.1291/hypres.28.565
  10. Guggino, S.E., Wagner, J.A., Snowman, A.M., Hester, L.D., Sacktor, N., and Snyder, S.H. (1988). Phenylalkylamine-sensitive calcium channels in osteoblast-like osteosarcoma cells. J Biol Chem, 263, 10155-61
  11. Jiliang, L.I., Randall, L.D., David, B.B., and Charles, H.T. (2002). L-type calcium channels mediate mechanically induced bone formation in vivo. J Bone Mine. 17(10), 1795-1800 https://doi.org/10.1359/jbmr.2002.17.10.1795
  12. Kim, B.C., Kim, D.H., and Hur, M. (1988). A study of symptomatology, lipid change and hormonal change in the menopausal women. Korean J Obstet Gynecol. 31(6), 784-794
  13. Liberman, U.A., Weiss, S.R., Broll, J., Minne, H.W., Quan, H., Bell, N.H., Rodriguez-Portales, J., Downs, R.W. Jr., Dequeker, J., and Favus, M. (1995). Effect of oral alendronate on BMD and the incidence of fractures in postmenopausal osteoporosis. N Engl Med., 333(22), 1437-1443 https://doi.org/10.1056/NEJM199511303332201
  14. Luckey, M., Kagan, R., Greenspan, S., Bone, H., Kiel, R.D., Simon, J., Sackarowitz, J., Palmisano, J., Chen, E., Petruschke, R.A., and de Papp, A.E. (2004). Once-weekly alendronate 70 mg and raloxifene 60 mg daily in the treatment of postmenopausal osteoporosis. Menopause. 11(4), 405-415 https://doi.org/10.1097/01.GME.0000119981.77837.1F
  15. Mori, Y., Mikala, G., Vardi, G., Kobayashi, T., Koch, S., Wakamori, M., and Schwartz A. (1996). Molecular pharmacology of voltage-dependent calcium channels. Jpn J Pharmacol. 72, 83-109 https://doi.org/10.1254/jjp.72.83
  16. Nishiya, Y. and Sugimoto, S. (2001). Effects of various antihypertensive drugs on the function of osteoblast. Biol. Pharm. Bull. 24(6), 628-633 https://doi.org/10.1248/bpb.24.628
  17. Nishiya, Y., Kosaka, N., Uchii, M., and Suginoto, S. (2002). A potent 1,4-dihydropyridine L-type calcium channel blocker, benidipine, promotes osteoblast differentiation. Calcif Tissue Int. 70, 30-39 https://doi.org/10.1007/s00223-001-1010-5
  18. Reid, D.M., Hosking, D., Kendler, D., Brandi, M.L., Wark, J.D., Marques-Neto, J.F., Weryha, G., Vebruggen, N., Hutad, C.M., Mahlis, E.M., and Melton, M.E. (2008). A comparison of the effect of alendronate and risedronate on bone mineral density in postmenopausal women with osteoporosis: 24 month results from FACTS-International. Int J Clin Pract. 62(4), 575- 584 https://doi.org/10.1111/j.1742-1241.2008.01704.x
  19. Reiner, B. and Bertha, F. (2003). Osteoporosis. Springer
  20. Rosen, C.J., Hochberg, M.C., Bonnick, S.L., McClung, M., Miller, P., Broy, S., Kagan, R., Chen, E., Sambrook, P.N., Geusens, P., Ribot, C., Solimano, J.A., Ferrer-Barriendos, J., Gaines, K., Verbruggen, N., and Melton M.E. (2004). Alendronate produces greater effects than raloxifen on bone density and bone turnover in postmenopausal women with low bone density: results EFFECT International, J Int Medicine. 255, 503-511 https://doi.org/10.1111/j.1365-2796.2004.01317.x
  21. Schnitzer, T., Bone, H.G., Crepaldi, G., Adami, S., McClung, M., Kiel, D., Felsenberg, D., Recker, R.R., Tonino, R.P., Roux, C., Pinchera, A., Foldes, A.J., Greenspan, S.L., Levine, M.A., Emkey, R., Santora, A.C. 2nd., Kaur, A., Thompson, D.E., Yates, J., and Orloff, J.J. (2000), Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis., Aging(Milano). 12(1), 1-12
  22. Shun-ichi, H. and Gideon, A.R. (2003). Control of osteoblast function and regulation of bone mass., Nature. 423, 349-355 https://doi.org/10.1038/nature01660
  23. Takao, S. (1998). Current status of calcium-antagonists in Japan. Am J Cardio., 82(9B), 32R-34R
  24. Zekai, H., Bunyamin, B., Yuksel, O., Elif, C., and Halis, S. (2008). Protective effects of amlodipine and lacidipine on ovariectomy- induced bone loss in rats. Eur J Pharmaco, 579, 241-245 https://doi.org/10.1016/j.ejphar.2007.09.027